Real‐World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)‐Mutant Metastatic Non‐Small Cell Lung Cancer, From a US‐Based Clinico‐Genomic Database

Real‐World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)‐Mutant Metastatic Non‐Small Cell Lung Cancer, From a US‐Based Clinico‐Genomic Database

ABSTRACT Objectives Targeted therapies have been shown to improve outcomes in metastatic non‐small cell lung cancer (mNSCLC) with driver mutations. We evaluated the real‐world prevalence of human epidermal growth factor receptor 2 (HER2; ERBB2) tumor gene mutations among patients with mNSCLC and des...

Full description

Saved in:
Bibliographic Details
Main Authors: Sarah Waliany, Misako Nagasaka, Leah Park, Clara Lam, Zoe Jiang, Feng Lin, Joel W. Neal
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Cancer Medicine
Subjects:
advanced non–small cell lung cancer
ERBB2 mutation
HER2 mutation
targeted therapy
Online Access:https://doi.org/10.1002/cam4.70272
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70272

Similar Items